Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA grants priority review for AstraZeneca’s Calquence sNDA
The FDA will provide a decision on Calquence for the treatment of previously untreated mantle cell lymphoma by the first quarter of 2025. Credit: Narupon Promvichai from Pixabay.
The FDA will provide a decision on Calquence for the treatment of previously untreated mantle cell lymphoma by the first quarter of 2025. Credit: Narupon Promvichai from Pixabay.